Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Felcisetrag. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 20/20 | 1.00 |
| ▸ | HTR3A | P46098 | 16/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Felcisetrag SCHEMBL4361880 | 0.99 | HTR4 (0.98) | HTR4HTR3A | |
| SCHEMBL827475 | 0.93 | HTR4 (0.86) | HTR4HTR3A | |
| SCHEMBL828330 | 0.92 | HTR4 (0.85) | HTR4HTR3A | |
| SCHEMBL1724211 | 0.91 | HTR4 (0.87) | HTR4HTR3A | |
| SCHEMBL828734 | 0.91 | HTR4 (0.84) | HTR4HTR3A | |
| SCHEMBL1726589 | 0.89 | HTR4 (0.80) | HTR4HTR3A | |
| SCHEMBL828983 | 0.89 | HTR4 (0.82) | HTR4HTR3A | |
| SCHEMBL27850731 | 0.89 | HTR4 (0.82) | HTR4HTR3A | |
| SCHEMBL29397319 | 0.89 | HTR4 (0.82) | HTR4HTR3A | |
| SCHEMBL28074651 | 0.87 | HTR4 (0.80) | HTR4HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000674-A1 | PHARMACEUTICAL COMPOSITION | GEXVAL INC. (JP) | 2026-01-01 | — | — | US | claimed |
| EP-4548934-A1 | PHARMACEUTICAL COMPOSITION | Gexval Inc. (JP) | 2025-05-07 | — | — | EP | claimed |
| CN-119789869-A | Pharmaceutical composition | 嘉惟思远制药有限公司 | 2025-04-08 | — | — | CN | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| US-9975877-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-22 | — | — | US | claimed |
| US-20170081313-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-03-23 | — | — | US | claimed |
| US-20140057939-A1 | 5-HT4 RECEPTOR AGONIST COMPOUNDS FOR TREATMENT OF COGNITIVE DISORDERS | THERAVANCE, INC. (US) | 2014-02-27 | — | — | US | claimed |
| US-8377964-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2013-02-19 | — | — | US | claimed |
| EP-2419104-A2 | 5-HT4 RECEPTOR AGONIST COMPOUNDS FOR TREATMENT OF COGNITIVE DISORDERS | Theravance, Inc. (US) | 2012-02-22 | — | — | EP | claimed |
| EP-1899324-B1 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE INC (US) | 2011-11-30 | — | — | EP | claimed |
| US-20100249186-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-09-30 | — | — | US | claimed |
| US-7759363-B2 | Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists | THERAVANCE, INC. (US) | 2010-07-20 | — | — | US | claimed |
| US-20100029946-A1 | CRYSTALLINE FORM OF A BENZIMIDAZOLE-CARBOXAMIDE MEDICINAL COMPOUND | THERAVANCE, INC. (US) | 2010-02-04 | — | — | US | claimed |
| US-7622587-B2 | Crystalline form of a benzimidazole-carboxamide medicinal compound | THERAVANCE, INC. (US) | 2009-11-24 | — | — | US | claimed |
| EP-1899324-A2 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | Theravance, Inc. (US) | 2008-03-19 | — | — | EP | claimed |
| US-20070244157-A1 | Crystalline form of a benzimidazole-carboxamide medicinal compound | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-10-18 | — | — | US | claimed |
| US-7256294-B2 | Crystalline form of a benzimidazole-carboxamide medicinal compound | THERAVANCE, INC. (US) | 2007-08-14 | — | — | US | claimed |
| US-20060270854-A1 | Crystalline form of a benzimidazole-carboxamide medicinal compound | THERAVANCE, INC. | 2006-11-30 | — | — | US | claimed |
| WO-2006127815-A2 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2006-11-30 | — | — | WO | claimed |
| US-20060270652-A1 | Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists | THERAVANCE, INC. | 2006-11-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244157-A1 | Crystalline form of a benzimidazole-carboxamide medicinal compound | HTR4, HTR5A, HTR1A | HTR4 1/4885HTR3A 19/4885 |
| US-20260000674-A1 | PHARMACEUTICAL COMPOSITION | HTR4, IL4, FFAR4 | HTR4 1/4885HTR3A 14/4885 |
| US-20100249186-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR1A, HTR5A | HTR4 1/4885HTR3A 18/4885 |
| US-20060270652-A1 | Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists | HTR4, HTR1A, HTR5A | HTR4 1/4885HTR3A 18/4885 |
| US-20100029946-A1 | CRYSTALLINE FORM OF A BENZIMIDAZOLE-CARBOXAMIDE MEDICINAL COMPOUND | HTR4, HTR5A, HTR1A | HTR4 1/4885HTR3A 19/4885 |
| US-20170081313-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR1A, HTR5A | HTR4 1/4885HTR3A 18/4885 |
| US-20060270854-A1 | Crystalline form of a benzimidazole-carboxamide medicinal compound | HTR4, HTR5A, HTR1A | HTR4 1/4885HTR3A 19/4885 |
| US-20140057939-A1 | 5-HT4 RECEPTOR AGONIST COMPOUNDS FOR TREATMENT OF COGNITIVE DISORDERS | HTR4, HTR5A, HTR3B | HTR4 1/4885HTR3A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.